DOI: 10.1515/jpem-2023-0203 ISSN:

The therapeutic effect of oral desmopressin lyophilisate formulation in children with central diabetes insipidus

Hüseyin Anıl Korkmaz, Fulya Coşkunol, Vatan Barışık, Behzat Ozkan
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology and Child Health



We aimed to assess the efficacy of oral use of OLD in children with CDI.


Clinical, laboratory, and imaging characteristics of twenty-five children with CDI treated with OLD were evaluated.


Fourteen boys and eleven girls with a mean age of 52.37 months were evaluated. These children (mean weight and height at admission, 26.81 ± 14.8 kg vs. 92.52 ± 30 cm) presented with failure to thrive, irritability, prolonged fever, polyuria and hypernatremia (mean sodium level, 143.12 ± 8.6 mEq/L). At the time of hypernatremia, mean serum and urine osmolality were 298.2 ± 18 mOsm/kg and 160.20 ± 8.7 mOsm/kg, respectively. ADH levels were undetectable (<0.5 pmol/L) at admission in all cases. Oral administration of desmopressin lyophilisate (120 µg/tablet) was initiated at a dose of 5 μg/kg/day in two divided doses together with controlled water intake to avoid hyponatremia. Serum sodium levels normalised in a mean duration of 15.2 ± 16.4 h with a mean decline rate of 0.12 ± 0.04 mEq/L/h. Nine children needed rehospitalization because of hypernatremia due to non-compliance. Four episode of hyponatremia was observed. Weight gain and growth were normal during the mean follow-up duration of 37.79 ± 48.2 months.


Administration of OLD was practical and safe in the treatment of CDI in children with CNS malformations in this small retrospective series.

More from our Archive